HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects - J Buzón, Maria; Massanella, Marta; Llibre, Josep M; Esteve, Anna; Dahl, Viktor; Puertas, Maria C; Gatell, Josep M; Domingo, Pere; Paredes, Roger; Sharkey, Mark; Palmer, Sarah; Stevenson, Mario; et al. (Nature medicine, 2010)
Keywords: 631/326/596/1296; 631/92/436/2388; 692/699/249/1570/1901; Antiretroviral agents; Antiretroviral Therapy, Highly Active; Antiviral drugs; Biomedical and Life Sciences; Biomedicine; Cancer Research; Deoxyribonucleic acid; DNA; DNA, Complementary - genetics; DNA, Viral - genetics; Dosage and administration; Drug therapy; Health aspects; Highly active antiretroviral therapy; HIV; HIV infection; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - virology; HIV Integrase Inhibitors - pharmacology; HIV Integrase Inhibitors - therapeutic use; HIV Long Terminal Repeat - drug effects; HIV Long Terminal Repeat - genetics; HIV-1 - drug effects; HIV-1 - immunology; HIV-1 - physiology; Human immunodeficiency virus; Human immunodeficiency virus 1; Humans; Immunology; Infectious Diseases; Inhibitor drugs; letter; Metabolic Diseases; Molecular Medicine; Neurosciences; Polymerase Chain Reaction; Pyrrolidinones - pharmacology; Pyrrolidinones - therapeutic use; Raltegravir; Raltegravir Potassium; Virus Integration - drug effects; Virus Replication - drug effects; Virus Replication - physiology; United States